Switzerland’s largest drug maker, Roche Holdings AG, may make its first acquisition or purchase a drug compound developed in China this year, Bloomberg reported. Two executives from Roche’s drug-partnering unit based in China are looking for business opportunities, including licensing experimental medicines, Lee Babiss, the company’s head of Global Pharma Research, said. "They’re looking not only for those types of assets but also drug formulation, because know-how is really very, very deep in China," he said. Roche CEO Severin Schwan said the company is always looking for new acquisition targets. Roche is currently in the middle of a US$42.1 billion hostile takeover of its partner Genentech after it failed to secured a negotiated deal.